Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

Background: The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred in ≥ 25% of patients based on investigator reporting. However, AOE rates vary...

Full description

Bibliographic Details
Main Authors: Berman, E. (Author), Cortes, J. (Author), Croce, K. (Author), DeAngelo, D.J (Author), Deininger, M. (Author), Garasic, J.M (Author), Hall, T. (Author), Hochhaus, A. (Author), Januzzi, J.L (Author), Kantarjian, H. (Author), Kasner, S.E (Author), Kim, D.-W (Author), Mauro, M. (Author), McDonald, V. (Author), Naranjo, D. (Author), Nicolini, F. (Author), Petrie, M.C (Author), Pinilla-Ibarz, J. (Author), Seltzer, J. (Author), Srivastava, S. (Author), Xu, J. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
acute lymphoblastic leukemia
Acute lymphoblastic leukemia
adult
Adult
aged
Aged
Aged, 80 and over
antineoplastic agent
Antineoplastic Agents
Arterial Occlusive Diseases
artery occlusion
Article
cardiovascular risk
chronic myeloid leukemia
Chronic myeloid leukemia
clinical trial
female
Female
follow up
human
Humans
imidazole derivative
Imidazoles
incidence
Incidence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
major clinical study
male
Male
middle aged
Middle Aged
peripheral occlusive artery disease
phase 2 clinical trial
Philadelphia 1 chromosome
ponatinib
Precursor Cell Lymphoblastic Leukemia-Lymphoma
protein kinase inhibitor
Protein Kinase Inhibitors
protein tyrosine kinase inhibitor
pyridazine derivative
Pyridazines
Retrospective Studies
retrospective study
risk factor
Safety
standardization
Tyrosine kinase inhibitor
very elderly
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items